Fluorinated Alpha-2 Agonists for Extended Intravitreal Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering alpha-2 adrenergic receptor agents to the posterior segment of the eye are insufficient in achieving therapeutic levels for treating ocular conditions like glaucoma, due to rapid elimination via the anterior route and low aqueous humor/vitreous humor concentration ratios.
Innovation Solution
Development of ophthalmically therapeutic materials comprising alpha-2 adrenergic receptor agonists with enhanced anterior clearance properties, including liquid-containing compositions and polymeric drug delivery systems, which provide prolonged drug delivery and therapeutic benefits by selectively activating alpha-2 adrenergic receptors with increased vitreal half-life and aqueous humor/vitreous humor concentration ratios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing alpha-2 adrenergic receptor agonists are administered to the posterior segment of the eye, then neuroprotection and intraocular pressure reduction are achieved, but the drugs are rapidly eliminated via the anterior route with extremely short intravitreal half-lives
Solution Approach 1:
The patent modifies the chemical structure of alpha-2 adrenergic receptor agonists by introducing fluorine atoms at specific positions (e.g., 6-fluoro, 7-fluoro, 8-fluoro substitutions on the quinoxaline ring). These structural parameter changes alter the pharmacokinetic properties, specifically reducing anterior clearance rates and extending intravitreal half-lives from extremely short durations to therapeutically useful durations exceeding 3 hours
Solution Approach 2:
The patent creates composite molecular structures by combining the core alpha-2 adrenergic receptor agonist scaffold (brimonidine or apraclonidine) with fluorine-containing substituents. This composite approach merges the neuroprotective pharmacological activity of the parent compound with the extended ocular retention properties of the fluorinated derivatives
2Quantity of substance
If alpha-2 adrenergic receptor agonists are administered to treat anterior ocular conditions, then therapeutic effects are achieved, but the aqueous humor/vitreous humor concentration ratios are extremely small at steady-state
Solution Approach 1:
The fluorine substitution at positions 6, 7, or 8 on the quinoxaline ring systematically changes the molecular parameters to reduce anterior chamber penetration and clearance. This parameter modification increases the aqueous humor/vitreous humor concentration ratio by reducing the rate at which the drug is cleared from the vitreous to the anterior chamber
Data Source
Figure 1
AI summary
Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.